As CDMOs attend the J.P. Morgan Healthcare Conference in San Francisco, Jan. 13-16, analysts remain cautiously optimistic about the industry’s outlook in 2025.
From biologics to treatments for rare diseases, these drugs will bring unique production challenges that require advanced technologies and precise processes.
Contrasting the fortunes of other hot drug classes, it is possible that cell and gene therapies may have reached their apex. So, where do they go next?
The award to ReciBioPharm, a division of Recipharm, will support the global deployment of RNA continuous manufacturing technologies to low- and middle-income countries.
The CDMO will collaborate with Pandorum on its “liquid cornea” product, while providing an exclusive GMP suite for production of Genenta’s cell therapy.
With capacity increasing from six to 12 bioreactors for mammalian cell culture, the CDMO says Hillerød is the largest end-to-end biopharma manufacturing site in Europe.
While an effective disinfectant, the corrosive properties of chloramines can affect the performance and longevity of water treatment equipment. UV offers both economic and physical...
Improve bioreactor performance, accelerate process development from benchtop to production, assess respiratory efficiency with continuous CO2 monitoring, eliminate potential interferenc...
To achieve greater process stability and consistency between batches, it is important to understand both conventional stainless steel bioreactors and the rapidly growing single...
Over time and through repeated use, pH sensors in pharma and biotech applications are affected by their measuring environments. To ensure performance and accurate measurement,...
